Dogwood Therapeutics Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial
Reuters
Nov 11, 2025
<a href="https://laohu8.com/S/DWTX">Dogwood Therapeutics</a> Enrolls First 100 Patients in Halneuron Phase 2b Neuropathy Trial
Dogwood Therapeutics Inc. announced the enrollment of the first 100 patients in its ongoing Phase 2b HALT-CINP clinical trial evaluating Halneuron® for chemotherapy-induced neuropathic pain (CINP). The study is assessing the safety and effectiveness of Halneuron® compared to placebo in cancer patients with neuropathy resulting from previous platinum or taxane-based chemotherapy. Participants receive eight subcutaneous doses over 14 days, with follow-up at 28 days. The primary endpoint is the change in weekly average daily pain intensity scores from baseline to week four. An interim sample size analysis is scheduled for the fourth quarter of 2025, and final trial data are expected by mid-2026. Results from the study have not yet been presented.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1099246) on November 11, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.